Terns Pharma successfully shifted its focus after its GLP-1 obesity drug showed underwhelming results. By pivoting to its promising oncology asset for chronic myeloid leukemia, the company dramatically increased its value, culminating in a nearly $7 billion acquisition by Merck. This demonstrates the value of decisively abandoning struggling programs for high-potential ones.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

Servier's $2.5 billion acquisition of Day 1 Biopharmaceuticals is a strategic move to immediately gain a commercial oncology asset (Tovarofenib) and a related clinical pipeline. This highlights a common large pharma strategy of acquiring late-stage or already-marketed products to bypass early development risks and accelerate revenue growth.

Pfizer's R&D had a high clinical success rate but poor financial returns. CEO Albert Bourla diagnosed the problem not as a lack of scientific capability, but as a failure of focus. The R&D team was developing technically challenging drugs with miscalculated commercial potential, a leadership and governance issue he could fix in months.

The current biotech M&A boom is less about frantically plugging near-term patent cliff gaps (e.g., 2026-2027) and more about building long-term, strategic franchises. This forward-looking approach allows big pharma to acquire earlier-stage platforms and assets, signaling a healthier, more sustainable M&A environment.

The widespread reduction in internal R&D spending does not signal a retreat from innovation. Instead, companies are redirecting capital towards external opportunities, evidenced by a recent surge in multi-billion dollar M&A 'bolt-on' deals. This represents a strategic shift from building in-house to buying external assets.

Novartis's $2B acquisition of Xcelergy is a strategic "bolt-on" deal. With patents for its blockbuster allergy drug, Xolair, expiring, Novartis is proactively acquiring a next-generation asset to maintain its market leadership and protect future revenue streams.